Previous 10 | Next 10 |
2023-05-24 05:11:28 ET PTC Therapeutics ( NASDAQ: PTCT ) has decided to discontinue its preclinical and early research programs in its gene therapy platform and to reduce its workforce by ~8%. In addition, the company informed its CFO Emily Hill that her employment will be ...
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial PR Newswire - Conference call and webcast to be held at 5:00 pm EDT - SOUTH PLAINFIELD, N.J. , May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NA...
PTC Therapeutics Announces Strategic Pipeline Prioritization PR Newswire - Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX - SOUTH PLAINFIELD, N.J. , May 23, 2023 ...
2023-05-17 07:32:24 ET PTC Therapeutics' ( NASDAQ: PTCT ) drug sepiapterin met the main goal of a phase 3 trial to treat adults and children with phenylketonuria (PKU). PKU is an inherited metabolic disorder that causes an amino acid called phenylalanine to b...
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients PR Newswire - Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population (p<0.0001) - ...
2023-05-10 07:05:51 ET Summary Since publishing the last article on PTC Therapeutics, the company's share price has risen 31.28%, outperforming the iShares Biotechnology ETF and the S&P 500. Overall, risdiplam is the company's third-highest-grossing medicine, with sales of CHF...
2023-04-28 01:20:23 ET PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Conference Call April 27, 2023 04:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Matthew B. Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Emi...
2023-04-27 16:05:38 ET PTC Therapeutics press release ( NASDAQ: PTCT ): Q1 GAAP EPS of -$1.88 misses by $0.47 . Revenue of $220.4M (+47.9% Y/Y) beats by $19.92M . Net loss was $139.0 million for the first quarter of 2023, compared to net loss of $126.7 million ...
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , April 13, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call...
2023-03-24 07:54:10 ET Stuart Peltz, Chief Executive of rare-disease-focused biotech PTC Therapeutics ( NASDAQ: PTCT ), announced Friday that he is leaving the company after 25 years of service, handing the reins to current Chief Operating Officer Matthew Klein with immediate ...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....